Home » ViralClear to Test Antiviral Merimepodib for Advanced COVID-19
ViralClear to Test Antiviral Merimepodib for Advanced COVID-19
The FDA has approved ViralClear Pharmaceuticals’ application for a phase 2 study of its antiviral merimepodib as a possible COVID-19 treatment.
The trial will evaluate the oral antiviral in hospitalized COVID-19 patients who require supplemental oxygen or are on non-invasive ventilation or high-flow oxygen devices.
Merimepodib was previously being developed by Vertex Pharmaceuticals for chronic hepatitis C and psoriasis.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May